Keeping you up to date on recent developments in neurology, including: Personalized neuromodulation technique developed for obsessive-compulsive behavior; Improving pain research with new sensory neuron model; Tau end run prevents memory deficits, but not inflammation; Presenilin mutations affect neuronal stem cells.
Aging is not just wear and tear. It is an active process that is driven, at least in part, by chronic inflammation that is the result of immune cell dysfunction. Now, investigators at Stanford University have identified the metabolic switch underlying immune cell switch from function to dysfunction.
Keeping you up to date on recent developments in diagnostics, including: Increasing COVID-19 detection through secondary distribution of self-tests; COVID-19 and breath analysis; Saving lives from colorectal cancer; New classification scheme for glioblastomas.
In what is claimed as the first co-authored research between regulatory scientists at the U.S. FDA and a commercial manufacturer of organ-on-a-chip devices, CN Bio's Physiomimix system is shown to perform better than the current standard in vitro liver toxicity tests.
BioWorld looks at translational medicine, including: Tau end run prevents memory deficits, but not inflammation; SCLC subtypes have specific vulnerabilities; Turning tsetse fly meal to poison for sleeping sickness control.
A genome-wide look at variants in RNA-binding proteins has revealed that such variants were disproportionately linked to the risk of multiple psychiatric disorders.
Keeping you up to date on recent developments in orthopedics, including: New method heals skeletal injuries with synthetic bone; Designer cytokine makes paralyzed mice walk again; Osteoporosis drug could halve number of redo hip replacement operations.
LONDON – There’s mixed news about emerging variants of SARS-CoV-2, with Pfizer Inc. and Biontech SE reporting their vaccine Comirnaty maintains its protective effect against B 1.1.7, first detected in the U.K., while researchers in South Africa say virus variant 501Y.V2 is able to escape neutralization by both monoclonal antibodies and convalescent plasma from previously infected individuals.